Joshua Kueiyu Lin, M.D., Sc.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Comparative Effectiveness Research | 4 | 2022 | 713 | 1.480 |
Why?
|
| Electronic Health Records | 10 | 2023 | 4863 | 1.110 |
Why?
|
| Atrial Fibrillation | 7 | 2023 | 5186 | 1.010 |
Why?
|
| Pharmacoepidemiology | 3 | 2022 | 351 | 0.910 |
Why?
|
| Famotidine | 1 | 2022 | 17 | 0.810 |
Why?
|
| Medicare | 11 | 2023 | 6815 | 0.700 |
Why?
|
| International Normalized Ratio | 2 | 2021 | 382 | 0.660 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2020 | 216 | 0.590 |
Why?
|
| Inappropriate Prescribing | 1 | 2020 | 211 | 0.570 |
Why?
|
| Warfarin | 3 | 2023 | 1494 | 0.550 |
Why?
|
| Withholding Treatment | 1 | 2021 | 619 | 0.550 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2013 | 1127 | 0.530 |
Why?
|
| Venous Thromboembolism | 2 | 2021 | 1883 | 0.520 |
Why?
|
| Anticoagulants | 7 | 2023 | 4856 | 0.470 |
Why?
|
| Thrombocytopenia | 1 | 2023 | 1172 | 0.470 |
Why?
|
| Steroids | 1 | 2020 | 934 | 0.470 |
Why?
|
| Hospitalization | 4 | 2023 | 10810 | 0.450 |
Why?
|
| Dementia | 3 | 2023 | 2741 | 0.440 |
Why?
|
| Macrolides | 2 | 2021 | 204 | 0.420 |
Why?
|
| Pyloric Stenosis | 1 | 2012 | 28 | 0.420 |
Why?
|
| Respiratory Tract Infections | 1 | 2020 | 1008 | 0.400 |
Why?
|
| Proton Pump Inhibitors | 2 | 2022 | 551 | 0.390 |
Why?
|
| Outpatients | 1 | 2020 | 1595 | 0.390 |
Why?
|
| Drug Monitoring | 1 | 2017 | 960 | 0.370 |
Why?
|
| Blood Coagulation | 1 | 2017 | 1171 | 0.370 |
Why?
|
| Amoxicillin | 1 | 2012 | 179 | 0.370 |
Why?
|
| Delirium | 1 | 2023 | 1699 | 0.360 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 1075 | 0.360 |
Why?
|
| Stroke | 3 | 2023 | 9739 | 0.350 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2012 | 2538 | 0.350 |
Why?
|
| Kidney Failure, Chronic | 1 | 2023 | 2504 | 0.340 |
Why?
|
| Laryngoscopes | 1 | 2011 | 147 | 0.340 |
Why?
|
| Peptic Ulcer | 1 | 2011 | 214 | 0.330 |
Why?
|
| Histamine H2 Antagonists | 1 | 2011 | 168 | 0.330 |
Why?
|
| Antipsychotic Agents | 1 | 2023 | 3075 | 0.320 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 2307 | 0.310 |
Why?
|
| Decision Support Techniques | 2 | 2020 | 2004 | 0.300 |
Why?
|
| Insurance Claim Review | 3 | 2021 | 744 | 0.280 |
Why?
|
| Secondary Prevention | 1 | 2013 | 1470 | 0.280 |
Why?
|
| Cleft Lip | 1 | 2012 | 512 | 0.270 |
Why?
|
| Aged | 23 | 2023 | 171163 | 0.270 |
Why?
|
| Progesterone | 1 | 2011 | 751 | 0.270 |
Why?
|
| Anti-Bacterial Agents | 4 | 2017 | 7473 | 0.270 |
Why?
|
| Cleft Palate | 1 | 2012 | 596 | 0.270 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 1325 | 0.260 |
Why?
|
| Video Recording | 1 | 2011 | 977 | 0.260 |
Why?
|
| Primary Prevention | 1 | 2013 | 1187 | 0.260 |
Why?
|
| Laryngoscopy | 1 | 2011 | 714 | 0.260 |
Why?
|
| United States | 15 | 2023 | 72909 | 0.250 |
Why?
|
| Hormone Replacement Therapy | 1 | 2011 | 752 | 0.250 |
Why?
|
| Aspirin | 2 | 2013 | 3135 | 0.230 |
Why?
|
| Estrogens | 1 | 2011 | 1528 | 0.230 |
Why?
|
| Intubation, Intratracheal | 1 | 2011 | 1359 | 0.210 |
Why?
|
| Humans | 39 | 2023 | 765926 | 0.200 |
Why?
|
| Omeprazole | 1 | 2022 | 106 | 0.190 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 1802 | 0.190 |
Why?
|
| Administration, Oral | 4 | 2023 | 4016 | 0.190 |
Why?
|
| Fibrinolytic Agents | 1 | 2011 | 2076 | 0.190 |
Why?
|
| Algorithms | 5 | 2023 | 14064 | 0.180 |
Why?
|
| Comoros | 1 | 2020 | 12 | 0.180 |
Why?
|
| Haloperidol | 1 | 2023 | 394 | 0.180 |
Why?
|
| Databases, Factual | 5 | 2022 | 8060 | 0.170 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 5509 | 0.170 |
Why?
|
| Catheter Ablation | 1 | 2013 | 2787 | 0.170 |
Why?
|
| Comorbidity | 3 | 2020 | 10575 | 0.170 |
Why?
|
| Clinical Coding | 1 | 2021 | 187 | 0.170 |
Why?
|
| Abnormalities, Drug-Induced | 2 | 2013 | 336 | 0.160 |
Why?
|
| Logistic Models | 5 | 2013 | 13273 | 0.150 |
Why?
|
| Female | 24 | 2023 | 396141 | 0.150 |
Why?
|
| Retrospective Studies | 10 | 2023 | 81537 | 0.150 |
Why?
|
| Risk Factors | 9 | 2022 | 74850 | 0.150 |
Why?
|
| Geography | 1 | 2020 | 651 | 0.150 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 419 | 0.140 |
Why?
|
| Heart Defects, Congenital | 2 | 2012 | 4712 | 0.130 |
Why?
|
| Cohort Studies | 5 | 2023 | 41680 | 0.130 |
Why?
|
| Age Factors | 3 | 2020 | 18382 | 0.130 |
Why?
|
| Aged, 80 and over | 8 | 2023 | 59496 | 0.130 |
Why?
|
| Adult | 12 | 2023 | 223088 | 0.130 |
Why?
|
| Drug Therapy, Combination | 3 | 2021 | 6306 | 0.120 |
Why?
|
| Male | 17 | 2023 | 363815 | 0.120 |
Why?
|
| Quality Control | 1 | 2017 | 835 | 0.120 |
Why?
|
| Drug Utilization | 1 | 2020 | 1187 | 0.120 |
Why?
|
| Pyridones | 1 | 2020 | 816 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 10380 | 0.120 |
Why?
|
| Interviews as Topic | 2 | 2012 | 2740 | 0.110 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 5364 | 0.110 |
Why?
|
| Risk | 4 | 2013 | 9599 | 0.110 |
Why?
|
| Pregnancy Trimester, First | 3 | 2013 | 917 | 0.110 |
Why?
|
| Natural Language Processing | 1 | 2023 | 1198 | 0.110 |
Why?
|
| Data Mining | 1 | 2018 | 559 | 0.110 |
Why?
|
| Nasal Decongestants | 1 | 2013 | 29 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2020 | 1881 | 0.110 |
Why?
|
| Area Under Curve | 1 | 2017 | 1637 | 0.110 |
Why?
|
| Neoplasms | 1 | 2022 | 22340 | 0.110 |
Why?
|
| Erythromycin | 1 | 2012 | 114 | 0.100 |
Why?
|
| Sex Factors | 2 | 2020 | 10611 | 0.100 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 15645 | 0.100 |
Why?
|
| Case-Control Studies | 5 | 2013 | 22228 | 0.100 |
Why?
|
| Clarithromycin | 1 | 2012 | 87 | 0.100 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2023 | 2136 | 0.100 |
Why?
|
| Liver Cirrhosis | 1 | 2023 | 1961 | 0.100 |
Why?
|
| Nonprescription Drugs | 1 | 2013 | 119 | 0.100 |
Why?
|
| Risk Assessment | 4 | 2022 | 24275 | 0.100 |
Why?
|
| Tetracyclines | 1 | 2011 | 64 | 0.090 |
Why?
|
| Azithromycin | 1 | 2012 | 202 | 0.090 |
Why?
|
| Pandemics | 2 | 2022 | 8721 | 0.090 |
Why?
|
| Biological Products | 1 | 2020 | 947 | 0.090 |
Why?
|
| Colorectal Neoplasms | 1 | 2011 | 6958 | 0.090 |
Why?
|
| Validation Studies as Topic | 1 | 2011 | 162 | 0.090 |
Why?
|
| Analgesics | 1 | 2017 | 1057 | 0.090 |
Why?
|
| Middle Aged | 8 | 2023 | 223016 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2022 | 2339 | 0.090 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2013 | 2769 | 0.090 |
Why?
|
| Glottis | 1 | 2011 | 214 | 0.090 |
Why?
|
| Nitrates | 1 | 2011 | 260 | 0.080 |
Why?
|
| ROC Curve | 1 | 2017 | 3612 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 1604 | 0.080 |
Why?
|
| State Medicine | 1 | 2011 | 219 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2020 | 2031 | 0.080 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 1481 | 0.080 |
Why?
|
| Acute Disease | 1 | 2020 | 7236 | 0.080 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 2726 | 0.080 |
Why?
|
| Stroke Volume | 2 | 2023 | 5595 | 0.080 |
Why?
|
| Heart Failure | 3 | 2023 | 11837 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2020 | 3053 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 15401 | 0.070 |
Why?
|
| Quality Indicators, Health Care | 1 | 2017 | 1804 | 0.070 |
Why?
|
| Incidence | 3 | 2020 | 21513 | 0.070 |
Why?
|
| Time Factors | 4 | 2021 | 40097 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2020 | 5339 | 0.070 |
Why?
|
| Ticlopidine | 1 | 2011 | 730 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2021 | 13042 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 15878 | 0.060 |
Why?
|
| Ventricular Function, Left | 1 | 2018 | 3930 | 0.060 |
Why?
|
| Patient Selection | 1 | 2017 | 4248 | 0.060 |
Why?
|
| Hemorrhage | 1 | 2017 | 3466 | 0.060 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 3690 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2020 | 65194 | 0.060 |
Why?
|
| Research Design | 1 | 2021 | 6204 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 20133 | 0.060 |
Why?
|
| Prognosis | 2 | 2022 | 29890 | 0.060 |
Why?
|
| International Classification of Diseases | 2 | 2021 | 934 | 0.060 |
Why?
|
| Self Report | 2 | 2013 | 3768 | 0.060 |
Why?
|
| Smoking | 1 | 2020 | 9082 | 0.060 |
Why?
|
| Pregnancy | 4 | 2013 | 30230 | 0.050 |
Why?
|
| Length of Stay | 1 | 2017 | 6486 | 0.050 |
Why?
|
| Young Adult | 2 | 2020 | 59857 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2013 | 9656 | 0.050 |
Why?
|
| Equipment Design | 1 | 2011 | 3490 | 0.050 |
Why?
|
| Adolescent | 2 | 2022 | 88811 | 0.050 |
Why?
|
| Receptors, Angiotensin | 1 | 2023 | 141 | 0.050 |
Why?
|
| Propensity Score | 2 | 2022 | 1971 | 0.050 |
Why?
|
| Population Surveillance | 1 | 2012 | 2596 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2011 | 6321 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 10727 | 0.050 |
Why?
|
| Recurrence | 1 | 2013 | 8492 | 0.050 |
Why?
|
| Alzheimer Disease | 1 | 2022 | 8722 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2011 | 2969 | 0.040 |
Why?
|
| Neprilysin | 1 | 2023 | 484 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2021 | 12235 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 12059 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2023 | 1238 | 0.040 |
Why?
|
| Medical Record Linkage | 1 | 2018 | 286 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2011 | 5088 | 0.030 |
Why?
|
| Hydroxychloroquine | 1 | 2021 | 429 | 0.030 |
Why?
|
| Embolism | 1 | 2020 | 401 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2023 | 1060 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2013 | 26380 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 21069 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 1513 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2023 | 2028 | 0.030 |
Why?
|
| Receptor, erbB-2 | 1 | 2022 | 2592 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 2013 | 482 | 0.020 |
Why?
|
| Patient Participation | 1 | 2020 | 1447 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2018 | 2353 | 0.020 |
Why?
|
| Cause of Death | 1 | 2020 | 3715 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2011 | 42510 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2022 | 6251 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 2782 | 0.020 |
Why?
|
| Canada | 1 | 2013 | 2120 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 2915 | 0.020 |
Why?
|
| Mental Recall | 1 | 2011 | 1217 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 14643 | 0.020 |
Why?
|
| Maternal Exposure | 1 | 2011 | 1098 | 0.010 |
Why?
|
| Child | 1 | 2011 | 80568 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 11858 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 2270 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2022 | 15802 | 0.010 |
Why?
|
| Obesity | 1 | 2021 | 13082 | 0.010 |
Why?
|
| Quality of Life | 1 | 2020 | 13463 | 0.010 |
Why?
|